Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F21%3A10426568" target="_blank" >RIV/00064203:_____/21:10426568 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/21:10426568

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Nxsf3Ww7O_" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Nxsf3Ww7O_</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00431-021-04077-0" target="_blank" >10.1007/s00431-021-04077-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease

Popis výsledku v původním jazyce

Studies showing a substantial frequency of dermatologic complications in paediatric Crohn&apos;s disease (CD) patients on anti-tumour necrosis factor (TNF) therapy preferentially include patients treated with infliximab. We aimed to identify risk factors for the cumulative incidence of skin complications in a paediatric cohort receiving either adalimumab or infliximab and found an association between current skin complications and the patient&apos;s current clinical condition. This study retrospectively evaluated dermatologic complications in an inception cohort of 100 paediatric CD patients receiving the first anti-TNF (Motol PIBD cohort). Patient data were collected every 3 months. The lesions were classified as psoriatic, atopic dermatitis, or others. We used Cox regression to evaluate the association between predefined variables and the time to complication and a generalised linear mixed model to assess the association between the patient&apos;s current condition and the occurrence of complications. Among the 89 included children, 35 (39%) presented with dermatologic lesions. The only predictor associated with any complication was infliximab (versus adalimumab) therapy (hazard ratio [HR]: 2.07; 95% confidence interval [CI]: 1.03-4.17; p = 0.04). Infliximab therapy (HR: 5.5; 95%CI: 1.59-19.06; p = 0.01) and a family history of atopy (HR: 3.4; 95%CI 1.35-8.57, p = 0.002) were associated with early manifestation of atopic dermatitis. Lower C-reactive protein levels (odds ratio [OR], 0.947; 95% CI, - 0.898 to 0.998; p = 0.046) and infliximab (versus adalimumab) were associated with the occurrence of any dermatologic complications (OR, 5.93; 95% CI, 1.59-22.07; p = 0.008).Conclusion: The frequency of skin complications seems high in paediatric CD patients treated with anti-TNF and is even higher in those treated with infliximab. What is Known: .The dermatologic complications occur during treatment with anti-tumour necrosis factor. .The frequency of skin complications in paediatric patients with Crohn&apos;s disease is high. What is New: .Infliximab (vs. adalimumab) was identified as a strong risk factor for the cumulative incidence of skin complications. .Lower C-reactive protein levels were associated with the current occurrence of dermatologic complications.

Název v anglickém jazyce

Risk factors for dermatological complications of anti-TNF therapy in a cohort of children with Crohn's disease

Popis výsledku anglicky

Studies showing a substantial frequency of dermatologic complications in paediatric Crohn&apos;s disease (CD) patients on anti-tumour necrosis factor (TNF) therapy preferentially include patients treated with infliximab. We aimed to identify risk factors for the cumulative incidence of skin complications in a paediatric cohort receiving either adalimumab or infliximab and found an association between current skin complications and the patient&apos;s current clinical condition. This study retrospectively evaluated dermatologic complications in an inception cohort of 100 paediatric CD patients receiving the first anti-TNF (Motol PIBD cohort). Patient data were collected every 3 months. The lesions were classified as psoriatic, atopic dermatitis, or others. We used Cox regression to evaluate the association between predefined variables and the time to complication and a generalised linear mixed model to assess the association between the patient&apos;s current condition and the occurrence of complications. Among the 89 included children, 35 (39%) presented with dermatologic lesions. The only predictor associated with any complication was infliximab (versus adalimumab) therapy (hazard ratio [HR]: 2.07; 95% confidence interval [CI]: 1.03-4.17; p = 0.04). Infliximab therapy (HR: 5.5; 95%CI: 1.59-19.06; p = 0.01) and a family history of atopy (HR: 3.4; 95%CI 1.35-8.57, p = 0.002) were associated with early manifestation of atopic dermatitis. Lower C-reactive protein levels (odds ratio [OR], 0.947; 95% CI, - 0.898 to 0.998; p = 0.046) and infliximab (versus adalimumab) were associated with the occurrence of any dermatologic complications (OR, 5.93; 95% CI, 1.59-22.07; p = 0.008).Conclusion: The frequency of skin complications seems high in paediatric CD patients treated with anti-TNF and is even higher in those treated with infliximab. What is Known: .The dermatologic complications occur during treatment with anti-tumour necrosis factor. .The frequency of skin complications in paediatric patients with Crohn&apos;s disease is high. What is New: .Infliximab (vs. adalimumab) was identified as a strong risk factor for the cumulative incidence of skin complications. .Lower C-reactive protein levels were associated with the current occurrence of dermatologic complications.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30209 - Paediatrics

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Pediatrics

ISSN

0340-6199

e-ISSN

—

Svazek periodika

180

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

8

Strana od-do

3001-3008

Kód UT WoS článku

000641211400001

EID výsledku v databázi Scopus

2-s2.0-85111988159